US Stock MarketDetailed Quotes

CATX Perspective Therapeutics

Watchlist
  • 4.0100
  • +0.3800+10.47%
Close Jan 24 16:00 ET
  • 4.0200
  • +0.0100+0.25%
Post 20:01 ET
271.03MMarket Cap-2.69P/E (TTM)

Perspective Therapeutics Key Stats

Perspective Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 4 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 151.330K--
--2024/Q4-- / 286.400K--
Nov 12, 20242024/Q3369.000K / 237.910K--
Aug 12, 20242024/Q2526.000K / 135.630K--
May 15, 20242024/Q1325.000K / 68.800K--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 151.330K--
--2024/Q4-- / 286.400K--
Nov 12, 20242024/Q3369.000K / 237.910K--
Aug 12, 20242024/Q2526.000K / 135.630K--
May 15, 20242024/Q1325.000K / 68.800K--

Unlock Free Earnings Estimates

Perspective Therapeutics Earnings Reports

Read more

Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Jan 24, 2025

Strong Buy

  • Buy

    85.71%
  • Hold

    14.29%
  • Sell

    0.00%

Price Target

No Data